Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 486 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis (MS) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program

NCT03954717
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Shepherd CAN DO Program
Behavioral
Lead sponsor
Shepherd Center, Atlanta GA
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 7, 2026, 2:33 PM EDT
Recruiting Not applicable Interventional

Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients

NCT07392879
View directory record Official record
Conditions
Progressive Multiple Sclerosis, Depression
Interventions
Virtual Reality, Standard care
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

NCT04448977
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrevus
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 7, 2026, 2:33 PM EDT
Recruiting Not applicable Interventional

Blood Flow Restriction And Veterans With MS

NCT05433103
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Low-Load Exercise with Blood Flow Restriction, Low-Load Exercise Control Group
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Completed No phase listed Observational

PREG-MS: New England MS Pregnancy Registry

NCT03368157
View directory record Official record
Conditions
Multiple Sclerosis, Pregnancy Related
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Female only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 7, 2026, 2:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

NCT03109288
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 1 Interventional

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

NCT01764737
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
VX15/2503, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Cullman, Alabama • Aurora, Colorado • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Sep 7, 2026, 2:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT05359653
View directory record Official record
Conditions
Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Benign
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Recruiting Not applicable Interventional

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

NCT07376772
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Interventions
wearable focal vibration therapy
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low Fat Diet for Fatigue in MS

NCT03322982
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Low-fat diet
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oxidative Pathways in MS Fatigue

NCT02804594
View directory record Official record
Conditions
Progressive Multiple Sclerosis, Fatigue
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Recruiting Not applicable Interventional

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

NCT06390930
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Enrolling by invitation No phase listed Observational

CorEvitas Multiple Sclerosis (MS) Registry

NCT03291756
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2100
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Recruiting Not applicable Interventional

HOBSCOTCH-MS-Efficacy Trial

NCT06951919
View directory record Official record
Conditions
Multiple Sclerosis, Cognitive Dysfunction, Memory Disorders, Memory Impairment, Memory Dysfunction
Interventions
Home Based Self- management and Cognitive Training Changes lives in Multiple Sclerosis (HOBSCOTCH-MS)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
20 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 7, 2026, 2:33 PM EDT
Active, not recruiting Not applicable Interventional

Multiple Sclerosis Falls Insight Track

NCT05837949
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MS FIT: Falls Insight Track
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Restoration of Walking in Multiple Sclerosis Using Treadmill Training.

NCT00156676
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Body-weight supported treadmill, Lokomat
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Not applicable Interventional Results available

CPAP to Treat Cognitive Dysfunction in MS

NCT02544373
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
PAP therapy
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Not applicable Interventional

Exercise & Brain Health in MS

NCT02263339
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Aerobic Exercise, Stretching, Aerobic Exercise- Healthy Subjects
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

Treatment Interruption of Natalizumab

NCT01071083
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Sep 7, 2026, 2:33 PM EDT
Active, not recruiting No phase listed Observational

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

NCT05688436
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Diroximel Fumarate, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

NCT03737812
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
elezanumab, placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Berkeley, California • Carlsbad, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 2 Interventional Results available

Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)

NCT03091400
View directory record Official record
Conditions
Memory Disorders, Multiple Sclerosis
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 7, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

NCT00622700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 7, 2026, 2:33 PM EDT